Table 1.
Cohort characteristics among women receiving 26 Gy in five fractions (26Gy5F) between April and July 2020, by country and age at diagnosis
| Wales |
England |
|||||||
|---|---|---|---|---|---|---|---|---|
| All n = 213 | 50–59 years n = 86 | 60–69 years n = 84 | 70+ years n = 43 | All n = 3533 | 50–59 years n = 1441 | 60–69 years n = 1315 | 70+ years n = 777 | |
| Charlson Comorbidity Index | ||||||||
| Reported | 98% | 99% | 98% | 98% | 99% | 99% | 100% | 100% |
| 0 | 93% | 96% | 94% | 86% | 90% | 93% | 90% | 86% |
| 1 | 6% | 2% | 6% | 14% | 8% | 6% | 9% | 10% |
| 2+ | 0% | 1% | 0% | 0% | 2% | 1% | 2% | 4% |
| SCARF Index | ||||||||
| Reported | 98% | 99% | 98% | 98% | 99% | 99% | 100% | 100% |
| Fit | 87% | 92% | 88% | 76% | 83% | 89% | 82% | 75% |
| Mild-moderate | 13% | 8% | 12% | 24% | 15% | 11% | 17% | 22% |
| Severe | 0% | 0% | 0% | 0% | 2% | 1% | 1% | 4% |
| Stage | ||||||||
| Stage 0 | 5% | 5% | 7% | 2% | 10% | 13% | 9% | 8% |
| Stage 1 | 53% | 52% | 56% | 47% | 52% | 54% | 55% | 42% |
| Stage 2 | 40% | 43% | 36% | 44% | 37% | 32% | 35% | 47% |
| Stage 3A | 2% | 0% | 1% | 7% | 2% | 1% | 1% | 3% |
| Nodal involvement∗ | ||||||||
| N0 | 81% | 83% | 82% | 77% | - | - | - | - |
| N+ | 19% | 17% | 18% | 23% | 11% | 10% | 10% | 14% |
| NX | 0% | 0% | 0% | 0% | 89% | 90% | 90% | 86% |
| Surgery type | ||||||||
| Breast-conserving surgery | 92% | 92% | 93% | 88% | 87% | 88% | 90% | 82% |
| Mastectomy | 9% | 8% | 7% | 12% | 8% | 7% | 7% | 14% |
| Missing | 0% | 0% | 0% | 0% | 4% | 5% | 4% | 4% |
| Chemotherapy | ||||||||
| Neoadjuvant chemotherapy | 9% | 8% | 8% | 9% | 3% | 4% | 4% | 2% |
| Adjuvant chemotherapy | 22% | 24% | 20% | 21% | 22% | 24% | 23% | 17% |
| No chemotherapy | 70% | 67% | 71% | 70% | 74% | 72% | 73% | 81% |
| Radiotherapy target site | ||||||||
| Primary | - | - | - | - | 93% | 94% | 94% | 92% |
| Primary + regional nodes | - | - | - | - | 4% | 4% | 4% | 7% |
| Other/unknown | - | - | - | - | 2% | 3% | 2% | 2% |
| Time from diagnosis to radiotherapy | ||||||||
| <3 months | 24% | 24% | 21% | 26% | 24% | 25% | 22% | 24% |
| 3 months | 32% | 30% | 36% | 30% | 30% | 30% | 30% | 29% |
| 4 months | 15% | 15% | 17% | 9% | 15% | 14% | 15% | 18% |
| 5 months | 9% | 6% | 10% | 14% | 8% | 7% | 8% | 11% |
| 6 months and over | 21% | 24% | 17% | 21% | 24% | 25% | 25% | 18% |
SCARF, Secondary Care Administrative Records Frailty.
∗
For women diagnosed in England, axillary node dissection recorded within Hospital Episode Statistics or having stage 3A disease (N stage contribution defined as having N1/N2 disease) were used as a proxy for nodal involvement (N+); coded as NX otherwise.